Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. September 2018 07:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE Meeting

BOSTON, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment...
28. September 2018 07:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity

BOSTON, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment...
25. September 2018 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present at Ladenburg Thalmann 2018 Healthcare Conference

BOSTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment...
07. September 2018 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present at Morgan Stanley 16th Annual Global Healthcare Conference

BOSTON, Sept. 07, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment...
08. August 2018 16:01 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results

-- Completed Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Pro-opiomelanocortin (POMC) and Leptin Receptor (LEPR) Deficiency Obesity -- -- Announced New...
23. Juli 2018 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity

BOSTON, July 23, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment...
25. Juni 2018 16:01 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment...
20. Juni 2018 21:37 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

BOSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment...
18. Juni 2018 17:19 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

BOSTON, June 18, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment...
18. Juni 2018 07:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity

-- Further Improvements Observed in Bardet-Biedl Syndrome Patients; Initial Proof-of-Concept Data in Alström Syndrome Demonstrates Significant Weight Loss and Decreased Hunger ---- Rhythm Plans to...

Vorherige Seite